How do multifood allergy treatments compare?

Investigators compared omalizumab with omalizumab-facilitated multiallergen oral immunotherapy.

1

Omalizumab showed a higher treatment success rate compared to omalizumab-facilitated multiallergen oral immunotherapy in a randomized clinical trial.
2

The OUTMATCH trial involved 117 participants aged 1 to 55 with peanut and multiple food allergies, assessing treatment efficacy over 60 weeks.
3

In the intention-to-treat analysis, 36% of participants receiving omalizumab met the primary endpoint versus 19% receiving MOIT.
4

Serious adverse events occurred in 31% of the MOIT group, while none were reported in the omalizumab group.
5

The study highlighted distinct risk-benefit profiles for omalizumab and MOIT, emphasizing the need for individualized patient considerations.

1